Fundraising FoxCardio Flow
St. Paul, US · Founded 2010 · Delaware corporation
Find your way into Cardio Flow
Sign up to see every warm intro you have to Cardio Flow
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cardio Flow team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CardioFlow develops medical devices for interventional cardiology, specifically addressing critical limb-threatening ischemia through non-surgical therapies. The company serves interventional cardiologists and cardiovascular specialists.
Founders & leadership
MJ
Michael J. KallokExecutiveMichael J. Kallok is Executive Officer of Cardio Flow, which develops medical devices for interventional cardiology. He holds fellowships with the American College of Cardiology, American Heart Association, and American Institute of Medical and Biological Engineering, and has background in general management, company formation, fundraising, R&D, and clinical and regulatory affairs.
JA
Jihad A. MustaphaChief Medical Officer and Board of Directors
Board
GM
Gary M. PetrucciChairman, Founder and CEO
SC
Steven C. SimonBoard director
GM
Gary McCordBoard director
DB
David BrinkBoard director
Reported raises · per SEC filings
Form D private placements$14.8M disclosed across 12 of 14 rounds · 2015–2024
▶$400KraisedJun 2024 · 3 investors · Other Health CareRule 506(b)
▶$400KraisedJun 2024 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Steven SimonDirector
- Gary PetrucciDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $400K
- Proceeds to insiders
- $370K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedSep 2023 · 2 investors · Other Health CareRule 506(b)
▶$100KraisedSep 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David BrinkDirector
- Gary McCordDirector
- Steven SimonDirector
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $2M
- Amount sold
- $100K
- Minimum investment
- $25K
- Proceeds to insiders
- $160K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMay 2023 · 12 investors · Other Health CareRule 506(b)
▶$1.1MraisedMay 2023 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Steven SimonDirector
- David BrinkDirector
- Gary McCordDirector
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $210K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedSep 2021 · 3 investors · BiotechnologyRule 506(b)
▶$200KraisedSep 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Steven SimonDirector
- David BrinkDirector
- Gary PetrucciDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $12M
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedApr 2021 · 12 investors · BiotechnologyRule 506(b)
▶$2.7MraisedApr 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary PetrucciDirector
- Jihad MustaphaDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Steven SimonDirector
- Gary McCordDirector
- Offering amount
- $4.5M
- Amount sold
- $2.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$489KraisedJan 2021 · 7 investors · BiotechnologyRule 506(b)
▶$489KraisedJan 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael KallokExecutive Officer, Director
- Gary PetrucciDirector
- Jihad MustaphaDirector
- David BrinkDirector
- Gary McCordDirector
- Steven SimonDirector
- Offering amount
- $650K
- Amount sold
- $489K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMay 2020 · 7 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary McCordDirector
- Gary PetrucciDirector
- Steven SimonDirector
- David BrinkDirector
- Michael KallokExecutive Officer, Director
- Jihad MustaphaDirector
- Offering amount
- $3.5M
- Amount sold
- $1.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$360KraisedFeb 2020 · 2 investors · BiotechnologyRule 506(b)
▶$360KraisedFeb 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVID BRINKDirector
- STEVEN SIMONDirector
- GARY PETRUCCIDirector
- JIHAD MUSTAPHADirector
- GARY MCCORDDirector
- MICHAEL KALLOKExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $360K
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
HeartFlowHeartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.
American EndovascularOutpatient centers for treatment of peripheral artery disease.
ClearflowClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.
CorflowCorflow develops diagnostic and therapeutic solutions to restore healthy microvascular blood flow in the human body, serving the cardiovascular medical device industry.
Texas EndovascularTexas Endovascular provides minimally invasive interventional radiology treatments for vascular and musculoskeletal conditions, including varicose veins, peripheral artery disease, uterine fibroids, and knee osteoarthritis. The practice offers board-certified outpatient procedures designed to reduce recovery time and improve patient outcomes compared to traditional surgery.
MedflowMedFlow is a clinical operations platform designed for healthcare providers to automate and optimize clinical workflows, integrating with Athenahealth EHR systems. It offers templated preventative care workflows and consulting support to help provider organizations scale quality care delivery.
Companies working in the same space as Cardio Flow.
Frequently asked questions
- What does Cardio Flow do?
- CardioFlow develops medical devices for interventional cardiology, specifically addressing critical limb-threatening ischemia through non-surgical therapies. The company serves interventional cardiologists and cardiovascular specialists.
- How much funding has Cardio Flow raised?
- Cardio Flow has disclosed $14.8M raised across 12 of its 14 known rounds.
- Where is Cardio Flow headquartered?
- Cardio Flow is headquartered in St. Paul, US.